The authors have endeavoured to determine the place occupied by mast cells in bone tissue from the mode of action on the bone of their secretion products (metachromatic granules, heparin, prostaglandins), from their proliferation in reaction to some bone diseases (secondary mastocytosis) and from the bone lesions associated with systemic mastocytosis. Metachromatic granules are capable of chelating calcium, and heparin and prostaglandins stimulate bone resorption. However, the role of mast cells in bone remodeling through these mechanisms has not yet been demonstrated. Similarly, the significance of mastocytosis secondary to osteomalacia, renal osteodystrophy and ordinary osteoporosis remains hypothetical. Primary bone mastocytosis produces diffuse or circumscribed osteogenic, osteolytic or mixed lesions. While the pathogenesis of osteolytic forms can readily be explained by the actions of heparin and prostaglandins, that of the osteogenic forms is still mysterious. Finally, the histological profile, and even the nosological profile, of mast cell osteoporosis, a diffuse condition recently individualized, remain undetermined.
Download full-text PDF |
Source |
---|
Background/aims: Bruise is the extravasation of blood that may be mild or severe. Bone marrow mesenchymal stem cells (BM-MSCs) are one of the most promising cells used in regenerative medicine for treating many disorders. We aimed to evaluate the efficiency of BM-MSCs in treating cutaneous bruises.
View Article and Find Full Text PDFEur J Clin Invest
January 2025
Department of Surgical, Medical and Molecular Pathology and Critical Area, Laboratory of Biochemistry, University of Pisa, Pisa, Italy.
Sotatercept binds free activins by mimicking the extracellular domain of the activin receptor type IIA (ACTRIIA). Additional ligands are BMP/TGF-beta, GDF8, GDF11 and BMP10. The binding with activins leads to the inhibition of the signalling pathway and the deactivation of the bone morphogenic protein (BMP) receptor type 2.
View Article and Find Full Text PDFCancer Cell Int
January 2025
Department of Laboratory Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea.
Background: The prognosis of a plasma cell neoplasm (PCN) varies depending on the presence of genetic abnormalities. However, detecting sensitive genetic mutations poses challenges due to the heterogeneous nature of the cell population in bone marrow aspiration. The established gold standard for cell sorting is fluorescence-activated cell sorting (FACS), which is associated with lengthy processing times, substantial cell quantities, and expensive equipment.
View Article and Find Full Text PDFJ Orthop Surg Res
January 2025
Xuzhou Medical University Affiliated Stomatology Hospital, Xuzhou, 221002, Jiangsu Province, China.
Purpose: We aimed to explore the mechanism by which Boron-doped nano-hydroxyapatite (B-nHAp) facilitates the proliferation and differentiation of osteoblasts through controlled release of B.
Methods: B-nHAp characterization was accomplished by means of X-ray diffraction, scanning electron microscopy, inductively coupled plasma mass spectrometry, and transmission electron microscopy. Human bone marrow mesenchymal stem cells (hBMSCs) were subjected to flow cytometry, alizarin red S staining, and cell counting kit-8 assay for proliferation and differentiation determination.
Clin Epigenetics
January 2025
School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, 2308, Australia.
Background: Hypomethylating agents (HMA), such as azacytidine (AZA) and decitabine (DAC), are epigenetic therapies used to treat some patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome. HMAs act in a replication-dependent manner to remove DNA methylation from the genome. However, AML cells targeted by HMA therapy are often quiescent within the bone marrow, where oxygen levels are low.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!